Wave Life Sciences (WVE) director reports 14,000-share 10b5-1 stock sales

Rhea-AI Filing Summary

Wave Life Sciences Ltd. director reported stock transactions in company ordinary shares. On 12/08/2025, the insider exercised share options with an exercise price of $5.97 per share and sold 7,000 shares at $13 and another 7,000 shares at $14.

After these transactions, the reporting person directly owned 44,930 ordinary shares. The filing also shows share options to buy Wave Life Sciences ordinary shares at $5.97 that are fully vested and were transacted under a Rule 10b5-1 trading plan adopted on March 13, 2025.

Insider Trade Summary

Net Seller: 14,000 shares ($189,000)

Net Sell 5 txns

Insider Wagner Heidi L

Role Director

Sold 14,000 shs ($189K)

Type	Security	Shares	Price	Value
Exercise	Share Option (right to buy)	14,000	$0.00	--
Exercise	Ordinary Shares	7,000	$5.97	$42K
Sale	Ordinary Shares	7,000	$13.00	$91K
Exercise	Ordinary Shares	7,000	$5.97	$42K
Sale	Ordinary Shares	7,000	$14.00	$98K

Holdings After Transaction: Share Option (right to buy) — 7,000 shares (Direct); Ordinary Shares — 51,930 shares (Direct)

Footnotes (1)

1. The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. These share options are fully vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wagner Heidi L

(Last) (First) (Middle)

C/O WAVE LIFE SCIENCES LTD.,

733 CONCORD AVE.

(Street)

CAMBRIDGE MA 02138

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	12/08/2025		M(1)		7,000	A	$5.97	51,930	D
Ordinary Shares	12/08/2025		S(1)		7,000	D	$13	44,930	D
Ordinary Shares	12/08/2025		M(1)		7,000	A	$5.97	51,930	D
Ordinary Shares	12/08/2025		S(1)		7,000	D	$14	44,930	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$5.97	12/08/2025		M(1)			14,000	(2)	08/16/2026	Ordinary Shares	14,000	$0	7,000	D

Explanation of Responses:

1. The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.

2. These share options are fully vested.

	/s/ Heidi Wagner	12/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Wave Life Sciences (WVE) report in this Form 4?

The filing reports that a director of Wave Life Sciences exercised share options and sold company ordinary shares on 12/08/2025 under a pre-arranged Rule 10b5-1 trading plan.

How many Wave Life Sciences (WVE) shares were sold and at what prices?

The insider reported two sales: 7,000 ordinary shares at $13 per share and 7,000 ordinary shares at $14 per share on 12/08/2025.

What was the option exercise price in the Wave Life Sciences (WVE) insider transaction?

The share options exercised by the insider had an exercise price of $5.97 per Wave Life Sciences ordinary share.

How many Wave Life Sciences (WVE) shares does the insider own after the reported trades?

Following the reported transactions, the insider directly owned 44,930 ordinary shares of Wave Life Sciences.

Were the Wave Life Sciences (WVE) options in this Form 4 vested?

Yes. The filing states that the share options are fully vested, meaning they were exercisable when the transactions occurred.

Was a Rule 10b5-1 trading plan used for these Wave Life Sciences (WVE) insider trades?

Yes. The option exercise and related sales were made under a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.